Welcome to our dedicated page for Elicio Therapeutics SEC filings (Ticker: ELTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elicio Therapeutics, Inc. (Nasdaq: ELTX) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Elicio is a clinical-stage biotechnology company developing AMP-based, off-the-shelf immunotherapies for mKRAS-driven and other cancers, and its filings offer detailed insight into this development strategy, financial position, and risk profile.
Through this page, users can review annual reports on Form 10-K and quarterly reports on Form 10-Q, which typically describe Elicio’s clinical programs such as ELI-002 2P and 7P, the AMPLIFY-201 and AMPLIFY-7P trials in pancreatic and colorectal cancers, the broader AMP platform, and the company’s liquidity and operating expenses. Current reports on Form 8-K capture material events, including the release of clinical immunogenicity data, recommendations from the Independent Data Monitoring Committee for the Phase 2 AMPLIFY-7P study, publication of Phase 1 results in peer-reviewed journals, and the announcement of quarterly financial results.
Investors interested in insider activity can also look for Forms 3, 4 and 5, which disclose transactions by directors, officers and significant shareholders, where available. Proxy statements on Schedule 14A may provide information on governance matters and executive compensation related to Elicio’s leadership team and board.
On Stock Titan, Elicio’s SEC filings are updated in near real time as new documents are posted to EDGAR. AI-powered tools summarize lengthy filings, highlight key sections related to ELI-002, the AMP platform, clinical trial milestones, and cash runway, and help explain complex disclosures in accessible language. This allows users to quickly identify important changes in Elicio’s clinical development plans, financial condition, and risk factors without reading every page of each filing.
Elicio Therapeutics CEO Robert Connelly received new equity awards in the form of restricted stock units and stock options. On February 2, 2026, he was granted 73,600 restricted stock units of common stock at a price of $0, increasing his directly held common shares to 120,570.
He was also granted 147,200 stock options with an exercise price of $8.10 per share, all held directly. Both the RSUs and options vest 25% on February 2, 2027, with the remaining portions vesting over the following three years, contingent on his continued service to the company.
Elicio Therapeutics granted equity awards to its Chief Strategy and Financial Officer, Preetam Shah, on February 2, 2026. He received 24,000 restricted stock units, each representing one share of common stock at no cost on grant, and 47,900 stock options to buy common shares at an exercise price of $8.10 per share.
The RSUs vest 25% on February 2, 2027, with the rest vesting in annual installments over the following three years, contingent on continued service. The options vest 25% on February 2, 2027, with the remainder vesting in monthly installments over three years thereafter, also subject to continued service.
Elicio Therapeutics granted equity awards to its Chief Scientific Officer, Peter DeMuth. He received 20,800 restricted stock units at a price of
DeMuth also received a stock option for 41,600 shares of common stock with an exercise price of
Elicio Therapeutics, Inc. granted equity awards to executive Christopher Haqq, Executive Vice President, Head of R&D and Chief Medical Officer. On February 2, 2026, he received 25,400 restricted stock units (RSUs) of common stock at $0 cost and a stock option for 50,900 shares with an exercise price of $8.1 per share.
The 25,400 RSUs vest 25% on February 2, 2027, then annually over three additional years, contingent on continued service. The 50,900 options vest 25% on February 2, 2027, with the remainder vesting monthly over the following three years. After these grants, he directly holds 57,381 common shares and 50,900 options.
Elicio Therapeutics (ELTX) filed a resale registration covering up to 103,225 shares of common stock, issuable upon exercise of a warrant issued on June 3, 2025 to GKCC, LLC. The company will not receive proceeds from any sales by the selling stockholder; it may receive cash proceeds only if the warrant is exercised. The warrant is immediately exercisable, expires five years from issuance, and has a $7.75 per share exercise price, subject to a 49.99% beneficial ownership cap.
The selling stockholder may sell shares from time to time through public or private transactions at market or negotiated prices, using methods listed in the plan of distribution, including short sales after the registration statement is declared effective. ELTX trades on Nasdaq; the last reported sale price was $9.19 on November 12, 2025. As context, shares outstanding were 17,413,843 as of October 31, 2025; this is a baseline figure, not the amount being offered.
Elicio Therapeutics (ELTX) reported Q3 2025 results with a net loss of $10.1 million and total operating expenses of $8.0 million, down from $10.3 million a year ago. Year to date, net loss was $31.9 million.
Cash and cash equivalents were $20.6 million as of September 30, 2025. Management disclosed that these resources and expected needs raise substantial doubt about the company’s ability to continue as a going concern. Stockholders’ equity improved to $3.8 million from a $(11.3) million deficit at year-end 2024, reflecting capital actions.
During 2025, Elicio converted a $20.0 million senior secured convertible note (plus $0.3 million interest) into 3,500,573 shares in March, raised $9.2 million net in a January registered direct offering with accompanying warrants, generated $11.4 million net via ATM sales, and issued a $10.0 million senior secured promissory note in June with a warrant. Shares outstanding were 17,489,516 as of November 10, 2025.
Elicio Therapeutics (ELTX) filed an 8-K announcing financial results for the quarter ended September 30, 2025 and providing corporate updates. The company furnished a press release as Exhibit 99.1 with additional details.
The information furnished, including Exhibit 99.1, is not deemed “filed” under Section 18 of the Exchange Act and is not incorporated by reference unless expressly stated.
Actyus Private Equity SGIIC, S.A. filed a Schedule 13G/A reporting beneficial ownership of 268,564 shares of Elicio Therapeutics, Inc. common stock, representing
Elicio Therapeutics, Inc. (ELTX) filed a Form 8-K reporting a material event and included three exhibits: a press release dated
The filing supplies named exhibits that investors can review for trial details and corporate messaging; the 8-K itself does not disclose additional numerical trial outcomes in the provided excerpt, so readers should consult the attached press release, presentation, and Exhibit 99.2 for complete data.
Elicio Therapeutics reported that follow-up data from its Phase 1 AMPLIFY-201 study of ELI-002 were published in the peer-reviewed journal Nature Medicine. The company issued a press release announcing the publication, which is attached to this report as Exhibit 99.1 and incorporated by reference. The filing identifies the company as a Delaware corporation with common stock trading under the ticker ELTX on The Nasdaq Capital Market. This disclosure is limited to the publication notice and the inclusion of the press release as an exhibit; no financial results, trial outcomes, or operational actions are presented within the report.